← All organizations
Highest phase reached
Phase 3
Defunct as of May 1, 2019
Timeline
2000s
- Jul 1, 2000
Merrimack Pharmaceuticals— Founded
2010s
- Oct 22, 2015
irinotecan— NDA Secondary Org
- May 1, 2019
Merrimack Pharmaceuticals— Defunct
Drugs by trial phase (29 distinct, 31 trials)
Phase 3 (8 own, 0 via acquisition)
Phase 2 (12 own, 0 via acquisition)
Phase 1 (9 own, 0 via acquisition)
Indications
Studied for
- Adenocarcinoma
- Arthritis
- Arthritis, Rheumatoid
- Breast Neoplasms
- Carcinoma
- Carcinoma, Hepatocellular
- Carcinoma, Non-Small-Cell Lung
- Carcinoma, Ovarian Epithelial
- Carcinoma, Squamous Cell
- Carcinoma, Transitional Cell
- Colorectal Neoplasms
- Endometrial Neoplasms
- Esophageal Neoplasms
- Fallopian Tube Neoplasms
- Glioblastoma
- Glioma
- Head and Neck Neoplasms
- Lung Neoplasms
- Neoplasms
- Ovarian Neoplasms
- Pancreatic Neoplasms
- Psoriasis
- Sarcoma
- Small Cell Lung Carcinoma
- Squamous Cell Carcinoma of Head and Neck
- Stomach Neoplasms
- Triple Negative Breast Neoplasms
- Uveitis
Marketed drugs (1)
Recent trials (44)
- NCT03241810Lead sponsorPhase 2Aug 15, 2017
- NCT03119064CollaboratorPhase 1/Phase 2Jul 1, 2017
- NCT03076372Lead sponsorPhase 1Feb 22, 2017
- NCT03076372Study directorPhase 1Feb 22, 2017
- NCT02785068Lead sponsorPhase 1/Phase 2Jul 1, 2016
- NCT02640365CollaboratorPhase 1Nov 18, 2015
- NCT02538627Lead sponsorPhase 1Aug 1, 2015
- NCT02399137Lead sponsorPhase 2May 1, 2015
- NCT02399137Study directorPhase 2May 1, 2015
- NCT02387216Study directorPhase 2Feb 1, 2015
- NCT02387216Lead sponsorPhase 2Feb 1, 2015
- NCT02213744Lead sponsorPhase 2/Phase 3Jul 1, 2014
- NCT02022644CollaboratorPhase 1Feb 1, 2014
- NCT01774851Study directorPhase 2Jan 1, 2013
- NCT01774851Lead sponsorPhase 2Jan 1, 2013
Details
- Founded
- Cambridge, MA, US Jul 1, 2000
- Last known activity
- Aug 15, 2017